The FDA has approved Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day, pitching the rival diabetes combination into head-to-head competition. Both products combine a long acting insulin ...

N4 Pharma announced the appointment of Dr David H Solomon as its chief executive on Tuesday, and unveiled plans to rebrand as ...

N4 Pharma Plc a nommé David H Solomon au poste de directeur général . En identifiant David comme son successeur, Nigel Theobald, fondateur de la société, a quitté ses fonctions de ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that compared to ...

Adlyxin was discontinued in the US as of 2023, but lixisenatide can be found in Europe and other markets under the brand name Lyxumia. Lixisenatide is also a key ingredient in the diabetes drug ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 ...

Boston, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The GLP-1 analogue market is experiencing rapid expansion as the world faces rising obesity and diabetes prevalence, alongside strong demand for effective ...